The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, …

DOSING & MONITORING GUIDE INDICATIONS1 Crohn’s Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn’s disease in adults. Ulcerative Colitis: …

Jul 22, 2024 · These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.

Jun 20, 2024 · Ulcerative colitis patients may experience some serious side effects with Skyrizi, including severe allergic reactions, an increased risk of infections, and liver problems.

Jul 23, 2024 · Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulcers on the inner lining of the colon (large intestine).

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach …

For the treatment of Crohn’s disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced …

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This …

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s …

SKYRIZI is the first FDA-approved treatment for both ulcerative colitis (UC) and Crohn’s disease that specifically targets the interleukin-23 (IL-23) protein, one of the key proteins responsible …